• E-ISSN 2636-7688
  • Call Us: +90 422 341 06 60 / 1224
  • Email Us: dergi@inonu.edu.tr

Formerly Journal of Turgut Ozal Medical Center - ISSN 1300-1744

  • Annals of Medical Research



    Annals of Medical Research International Monthly Published Medical Journal

  • Annals of Medical Research

    In publication or citation search, the name similarities of the authors, typographical errors and institutional changes can cause confusion. To prevent this, researchers need to obtain a descriptive ID. ORCID (Open Researcher and Contributor ID) is a researcher-specific international URI with a 16-digit number. You can register for free for individual ORCID at http://orcid.org. Please indicate the ORCID number of all authors when submitting your article.

  • Annals of Medical Research


    Annals of Medical Research indexed in TÜBİTAK/ULAKBİM Tıp Veri Tabanı

  • Annals of Medical Research


    Annals of Medical Research indexed in

  • Annals of Medical Research
  • Annals of Medical Research
  • Annals of Medical Research
  • Annals of Medical Research

Dear readers,

Our journal is the official publication of Inonu University Medical Faculty and published uninterruptedly for 25 years. It was first published as the name of Inonu University Medical Journal and later as Journal of Turgut Ozal Medical Center. During its publication period, the journal accepted Turkish or English articles for publication.

Abstracting in an international index is just a paramount objective in the 25th year of the journal. Because of this goal, it was necessary to make a decision both in terms of journal name and publication language. It was important in this respect that the name of a general medical journal should be related to medicine again and it should be in English. For these reasons, the name of the journal was switched to Annals of Medical Research and its publication language is changed to in English. The logo of the journal was chosen as an apricot, which is the symbol of our city Malatya, the world capital of apricot. I hope the journal succeeds with its new name. Annals of Medical Research is It is published monthly.

Editor-in-Chief
Cuneyt Kayaalp

 

Imatinib mesylate in first-line treatment of chronic myeloid leukemia (p. 1737-43)

Imatinib mesylate in first-line treatment of chronic myeloid leukemia (p. 1737-43)

Omer Ekinci1, Ismet Kizilkaya2
1Firat University Faculty of Medicine, Department of Hematology, Elazig, Turkey
2Yuzuncu Yil University Faculty of Medicine, Department of Hematology, Van, Turkey

Abstract

Objective: Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by clonal proliferation of myeloid cells. In this study we aimed to present our experience in patients with CML who used imatinib mesylate, a tyrosine kinase inhibitor (TKI).
Aim: Sixty nine patients who were diagnosed with CML and were treated with first-generation TKI ( in the form of imatinib mesylate) as initial treatment between 2006 and 2018 were included in this retrospective study. The demographic characteristics, response rates (hematologic, cytogenetic and molecular), adverse events and overall survival (OS) rates were retrospectively analyzed.
Results: There were 28 male and 41 female patients with a median age of 49.3. Hematologic, cytogenetic and molecular responses to TKI treatment were evaluated according to the 2013 guidelines of European Leukemia Net (ELN). The complete hematologic response (CHR) rate at three months was 97.1%, the complete cytogenetic response (CCR) rate at 12 months was 73.4%, and the major molecular response (MMR) at 18 months was 77.8%. The most common adverse events were cytopenia (13%), edema (10.1%), nausea/vomiting (7.2%), and musculoskeletal pain (5.8%). The mean follow-up period was 40.4 months for all CML patients, with an overall survival (OS) rate of 84.6% during follow-up.
Conclusion: As a real life data in our population, our results were consistent with those reported in the literature. Drug-related adverse events were minimal and tolerable. Long-term survival and disease-free survival can be achieved with proper cytogenetic and molecular monitoring under imatinib treatment and, if necessary, a change in medication.

Keywords: Chronic myeloid leukemia; tyrosine kinase inhibitor; imatinib.

 

DOWNLOAD
doi: 10.5455/annalsmedres.2019.08.449

DownloadXML


Contact us

+90 422 341 06 60 / 1224 - University

+90 422 341 06 60 Department


Location

Inonu University Faculty of Medicine

Malatya, 44069

Turkey


Send us email

dergi@inonu.edu.tr

dergi@inonu.edu.tr


demo

Annals of Medical Research is the scientific official journal of the Inonu University Faculty of Medicine. It is published monthly. The essential aim of the Annals of Medical Research is to publish scientifically high quality clinical and experimental research articles on fields of medicine which can contribute to the literature data. In addition, review articles, case reports, editorials, letters to the editors and manuscripts on publication ethics and medical history, which can contribute to the education and practices of physicians and health sector professionals within the scope of the journal’s target audience and which can increase the level of scientific communication between the authors and readers, are included in the scope of the journal.

 

Recent News

All News

Links

Certificate of General Impact Factor

Email Newsletter

Sign up for the latest Inonu University Our new article, updates....